ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,099.96
1.02%
Dow Jones
38,239.66
0.40%
US Dollar vs MXN
17.1601
0.00%
Brent Oil
88.165
0.00%
Bitcoin
62,661.58
-1.69%
Registration Strip Icon for charts Regístrate para obtener gráficos en tiempo real, herramientas de análisis y precios.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NASDAQ
  6. Kazia Therapeutics Ltd (KZIA)

  7. Kazia Therapeutics Ltd (KZIA) Noticias

KZIA Kazia Therapeutics Ltd

0.3887
0.01875 (5.07%)
26 Abr 2024 - Cerrado
Retrasado por 15 minutos
Nombre de la Acción Símbolo de la Acción Bolsa de Valores Tipo de Valor
Kazia Therapeutics Ltd KZIA NASDAQ Certificado de Depósito
  Variación del Día (ptos.) Variación del Día (%) Último Precio Hora
Upgrade Icon
0.01875 5.07% 0.3887 16:25:32
Precio de Apertura Precio Mínimo Precio Máximo Precio de cierre Precio Anterior
0.3646 0.357 0.389 0.37 0.36995
más cotizaciones de acciones »

Noticias Recientes

Fecha Hora Fuente Noticia
21/3/202407:52PRNUSKazia Therapeutics licenses paxalisib to Sovargen for..
13/3/202407:00PRNUSKazia announces presentation of new data at AACR Annual..
21/2/202415:19EDGAR2Form 424B3 - Prospectus [Rule 424(b)(3)]
21/2/202408:19EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
21/2/202406:30PRNUSKazia Therapeutics Reports Early Conclusion of Clinical..
14/2/202414:41EDGAR2Form SC 13G - Statement of acquisition of beneficial..
12/2/202417:35EDGAR2Form SC 13G - Statement of acquisition of beneficial..
05/2/202423:15EDGAR2Form EFFECT - Notice of Effectiveness
05/2/202415:19EDGAR2Form 424B3 - Prospectus [Rule 424(b)(3)]
18/1/202415:30EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
18/1/202406:30PRNUSKAZIA CONTINUES BOARD RENEWAL WITH TWO NEW APPOINTMENTS
12/1/202415:05EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
15/12/202316:26EDGAR2Form F-3 - Registration statement by foreign private issuers
06/12/202307:31EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
05/12/202317:02PRNUSKazia Therapeutics Announces Closing of $2 Million..
04/12/202315:05EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
01/12/202307:30EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
01/12/202307:00PRNUSKazia Therapeutics Announces $2 Million Registered Direct..
29/11/202315:19EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
29/11/202315:02EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
29/11/202306:01PRNUSKAZIA ANNOUNCES NON-BINDING LETTER OF INTENT FOR THE..
21/11/202306:30PRNUSKAZIA PROVIDES OVERVIEW OF PAXALISIB RELATED PRESENTATIONS..
20/11/202315:39EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
20/11/202315:30PRNUSKAZIA ANNOUNCES RECEIPT OF NASDAQ MINIMUM BID NOTIFICATION
15/11/202308:13EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
15/11/202307:30PRNUSKAZIA ANNOUNCES THE RELEASE OF PNOC022 CLINICAL STUDY..
10/11/202306:01PRNUSKAZIA ANNOUNCES PUBLICATION IN MOLECULAR CANCER THERAPEUTICS..
01/11/202315:17EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
01/11/202306:01PRNUSKAZIA THERAPEUTICS PROVIDES PRELIMINARY UPDATE FROM ONGOING..
26/10/202306:56EDGAR2Form 20-F - Annual and transition report of foreign private..
23/10/202307:30EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
23/10/202306:01PRNUSKAZIA THERAPEUTICS ANNOUNCES CLINICAL DATA AT ESMO 2023 FROM..
13/10/202315:08EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
11/10/202306:35EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
11/10/202306:01PRNUSKazia announces voluntary delisting from ASX
10/10/202314:04EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
06/10/202306:00EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
05/10/202306:01PRNUSKAZIA THERAPEUTICS ANNOUNCES PRESENTATIONS AT UPCOMING..
29/9/202306:01PRNUSKAZIA THERAPEUTICS ANNOUNCES ACCEPTANCE OF LATE-BREAKING..
29/9/202306:00EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
05/9/202306:02EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
11/8/202306:00EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
06/7/202315:15EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
06/7/202306:00PRNUSKAZIA'S PAXALISIB RECEIVES FAST TRACK DESIGNATION FROM FDA..
08/6/202306:00PRNUSKAZIA THERAPEUTICS ANNOUNCES PHASE II CLINICAL STUDY TO..
25/5/202306:01PRNUSKAZIA CEO, DR. JOHN FRIEND TO PARTICIPATE IN WHITE HOUSE..

Su Consulta Reciente

NASDAQ
KZIA
Kazia Therapeutics
Delayed Upgrade Clock
ADVFN Logo

México
Empresa
Negocios
Popular
Obtener la aplicación

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2024 ADVFN PLC - Todos los derechos reservados